Gastrointestinal Cancer

Gastrointestinal Cancer Target therapy

Improving Clinical Outcomes in Refractory RAS Wild-Type MCRC: The Velo Trial Shows Promise with Panitumumab and Trifluridine-Tipiracil

Gastrointestinal Cancer Immunotherapy

Pembrolizumab Enhances Overall Survival in First-Line Treatment of Advanced Biliary Tract Cancer: Keynote-966 Trial Findings

Gastrointestinal Cancer Immunotherapy

Improved Clinical Outcomes in Advanced HER2-Negative Gastric or Gastroesophageal Junction Cancer Patients with Pembrolizumab and Chemotherapy: Keynote-859 Study Update in the protocol-specified PD-L1–selected populations.

Gastrointestinal Cancer Immunotherapy

Phase III CONTACT-03 trial: Atezolizumab Addition to Cabozantinib Fails to Improve Outcomes in Advanced Renal Cell Carcinoma Patients Post-Immune Checkpoint Inhibitor Therapy

Gastrointestinal Cancer

Preoperative FOLFOX noninferior to preoperative chemoradiotherapy in locally advanced rectal cancer : Phase III PROSPECT trial

1692363550_WhatsApp Image 2023-08-18 at 3.55.38 PM.jpeg

Gastrointestinal Cancer Pancreatic Cancer

Neoadjuvant FOLFIRINOX fails to improve overall survival compared to upfront surgery in resectable pancreatic head cancer.

1692120224_WhatsApp Image 2023-08-15 at 8.22.13 PM.jpeg

Lung Cancer Bladder Cancer Breast Cancer CNS Cancers Colorectal Cancer COVID-19 Gastroesophageal Cancer Gastrointestinal Cancer Genomics/Genetics Geriatric Oncology Gynecologic Cancers Head and Neck Cancers Health-Care Policy Hepatobiliary Cancer Immunotherapy Integrative Oncology Kidney Cancer Legislation Leukemia Lymphoma Multiple Myeloma Neuroendocrine Tumors Palliative Care Pancreatic Cancer Prostate Cancer Sarcoma Skin Cancer Survivorship Symptom management Thyroid Cancer

FDA approval of bevacizumab biosimilar

On September 28th 2022, the FDA has approved Celltrion’s #bevacizumab biosimilar (bevacizumab-adcd) in six types of cancers which are: metastatic...

Gastrointestinal Cancer

Clinical trials summary

Expert Interviews

Oncology Watch Discussions